Current Status
Not Enrolled
Price
Free
Get Started
Course
Materials

Program Director

Jennifer G. Robinson, MD, MPH

Program Director

Raul D Santos, MD, MSc, PhD

Preventing Atherosclerotic Cardiovascular Disease in Patients with Diabetes Mellitus

The IAS recognizes that system-level improvements are needed in the prevention of ASCVD in patients with diabetes and that progress in CVD risk factor control is slowing. Based on US data, only 14% of patients meet targets for all A1C, BP, lipids, and nonsmoking status. 33-49% of patients still do not meet one or several targets for A1C, blood pressure, or lipids. This problem is exacerbated globally as even fewer meet these targets in many low-and middle-income countries.

The purpose of this video series are to provide a better understanding of the evidence-based management of the diabetic patient to reduce ASCVD risk with focused discussion on statins and newer diabetes drugs.

Each section is introducted by general lecture of the clinical prevalence and evidence. The panel will discuss the real world implications and provide practical implemtation advice.

Pre-activity information

This program is intended for health care professionals management or prevention of ASCVD and specifically those engaged in treating patients diabetes mellitus.

At the end of this activity the learner will have:

A better understanding of the evidence-based management of the diabetic patient to reduce ASCVD risk with focus on statins and newer diabetes drugs.

 

Jennifer G. Robinson MD, MPH

Disclosures Date of Disclosures
Research grants to Institution: Acasti, Amarin, Amgen, Astra Zeneca, Esai, Esperion, Merck, Novartis, Novo-Nordisk, Regeneron, Sanofi, Takeda.  10-12-2019
Consultant: Amgen, Medicines Company, Merck, Novartis, Novo-Nordisk, Pfizer, Regeneron, Sanofi 10-12-2019

Raul D Santos, MD, MSc, PhD

Disclosures Date of Disclosures
Consulting/Speaking/Research activities from: Akcea, Amgen, AstraZeneca, Biolab, Esperion, Kowa, Merck, Novo-Nordisk, Pfizer, and Sanofi/Regeneron. 10-12-2019

Peter Lansberg, MD, PhD

Disclosures Date of Disclosures
Unpaid Steering Committee: Kaneka 10-12-2019
Consultant/Advisory Board: Kaneka, Getz Pharma, Zora, Gendiag. 10-12-2019
Speaker Bureau: Amgen, Sanofi, Pfizer, Astra-Zeneca, Merck Sharp & Dohme, Getz Pharma; Gendiag 10-12-2019

Philip Barter, MBBS, PhD, FRACP

Disclosures Date of Disclosures
Consultant/Advisory Board/Speaker Honorarium for Amgen, Pfizer and Sanofi-Regeneron 10-12-2019

Khalid Al-Rasadi, MD

Disclosures Date of Disclosures
Honoraria for Speakers Bureau: AstraZeneca, Sanofi, Pfizer, Abbott. Advisory Boards: Sanofi, Aegerion. 10-12-2019

Dong Zhao, PhD

Disclosures Date of Disclosures
Research Grants to Institutions: Astra-Zeneca, Amgen, Boehringer-Ingelheim, Pfizer 10-12-2019

Peter Libby MD

Disclosures Date of Disclosures
Grant/Research support: Novartis 10-12-2019
Unpaid Consultant and/or Unpaid Steering or Executive Committee of Clinical Trials: Amgen, AstraZeneca, Esperion, GlaxoSmithKline, Kowa, Merck, Novartis, Pfizer, Sanofi-Aventis-Regeneron 10-12-2019
Scientific Advisory Board: IFM, Medimmune, DalCor, Amgen, Novartis, Corvidia, Olatec, Xbiotech 10-12-2019
Dr. Libby declines all personal compensation from pharma or device companies. 10-12-2019

Staff Disclosures

Nothing to disclose.

The International Atherosclerosis Society would like to thank Viatris (formerly Upjohn, a division of Pfizer), for their sponsorship of this education initiative.

Dextran Sulphate Lipoprotein Apheresis in FH and Beyond

See more...

Familial Hypercholesterolemia Homozygous Null Mutations

See more...

Management of Patients with Hypercholesterolemia during COVID-19 Pandemic

See more...

A Novel Case of Homozygous LDLRAP1 Gene Mutation causing Autosomal Recessive FH in Kuwait

See more...

Management Algorithm for Severe FH: Different Guidelines Implications

See more...

Novel Therapies and Future Developments to Treat Severe FH

See more...

Familial Hypercholesterolemia is a Preventable Disease: A Call for Action

See more...

Treatment of Severe FH Forms: PCSK9 Inhibitors

See more...

Treatment of Severe FH: The Role of Statins and Ezetimibe

See more...

Diagnosis and Natural History of Homozygous FH

See more...

Lipid Metabolism in Familial Hypercholesterolemia (FH)

See more...

« » page 1 / 3